Brown Advisory Inc. lifted its position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 671,103 shares of the biotechnology company’s stock after purchasing an additional 11,837 shares during the period. Brown Advisory Inc. owned 0.99% of Coherus Biosciences worth $6,074,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System increased its holdings in Coherus Biosciences by 16.5% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock worth $200,000 after buying an additional 3,122 shares during the last quarter. Boston Advisors LLC increased its holdings in Coherus Biosciences by 12.7% during the fourth quarter. Boston Advisors LLC now owns 33,060 shares of the biotechnology company’s stock worth $299,000 after buying an additional 3,725 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Coherus Biosciences by 4.1% during the fourth quarter. Bank of New York Mellon Corp now owns 222,542 shares of the biotechnology company’s stock worth $2,013,000 after buying an additional 8,766 shares during the last quarter. Roman Butler Fullerton & Co. purchased a new stake in Coherus Biosciences during the fourth quarter worth about $122,000. Finally, BlueMountain Capital Management LLC increased its holdings in Coherus Biosciences by 110.9% during the third quarter. BlueMountain Capital Management LLC now owns 32,257 shares of the biotechnology company’s stock worth $532,000 after buying an additional 16,960 shares during the last quarter. 96.51% of the stock is currently owned by institutional investors.
A number of research firms recently issued reports on CHRS. Zacks Investment Research downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, December 4th. Credit Suisse Group set a $25.00 price objective on shares of Coherus Biosciences and gave the stock a “buy” rating in a report on Thursday, March 7th. Finally, BidaskClub upgraded shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Coherus Biosciences has an average rating of “Buy” and an average target price of $27.20.
CHRS opened at $14.41 on Friday. The stock has a market capitalization of $998.04 million, a PE ratio of -4.48 and a beta of 3.64. The company has a debt-to-equity ratio of 8.29, a current ratio of 2.54 and a quick ratio of 2.49. Coherus Biosciences Inc has a twelve month low of $8.32 and a twelve month high of $20.66.
TRADEMARK VIOLATION NOTICE: “Coherus Biosciences Inc (CHRS) Position Lifted by Brown Advisory Inc.” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2019/03/17/coherus-biosciences-inc-chrs-position-lifted-by-brown-advisory-inc.html.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Featured Story: What is Call Option Volume?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.